Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue Estimates

Core Viewpoint - Y-mAbs Therapeutics, Inc. reported a quarterly loss of $0.16 per share, which was worse than the Zacks Consensus Estimate of a loss of$0.14, indicating a negative earnings surprise of -14.29% [1] Financial Performance - The company posted revenues of $18.46 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 21.03$20.45 million a year ago [2] - Over the last four quarters, Y-mAbs has surpassed consensus EPS estimates only once [2] Stock Performance - Y-mAbs shares have increased approximately 128% since the beginning of the year, significantly outperforming the S&P 500's gain of 25.2% [3] Future Outlook - The company's earnings outlook will be crucial for assessing future stock performance, particularly in light of management's commentary during the earnings call [4] - Current consensus EPS estimate for the upcoming quarter is -$0.12 on revenues of$25.71 million, and for the current fiscal year, it is -$0.62 on revenues of$92.76 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Y-mAbs belongs, is currently ranked in the top 35% of over 250 Zacks industries, suggesting a favorable industry outlook [8]